COVID-19 Infection: Targeting Possibilities for Treatment.

IF 3 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Tanweer Haider, Vishal Gour, Vikas Pandey, Indu Lata Kanwar, Rahul Tiwari, Monika Vishwakarma, Avijit Kumar Bakshi, Arkadeep Sarkar, Ravishankar Yadav, Sakshi Soni, Vandana Soni
{"title":"COVID-19 Infection: Targeting Possibilities for Treatment.","authors":"Tanweer Haider,&nbsp;Vishal Gour,&nbsp;Vikas Pandey,&nbsp;Indu Lata Kanwar,&nbsp;Rahul Tiwari,&nbsp;Monika Vishwakarma,&nbsp;Avijit Kumar Bakshi,&nbsp;Arkadeep Sarkar,&nbsp;Ravishankar Yadav,&nbsp;Sakshi Soni,&nbsp;Vandana Soni","doi":"10.1615/CritRevTherDrugCarrierSyst.2021035392","DOIUrl":null,"url":null,"abstract":"<p><p>The outbreak of novel coronavirus (nCoV) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019 in Wuhan, China, has posed an international public health emergency worldwide and forced people to be confined in their homes. This virus is of high-risk category and is declared a pandemic by the World Health Organization (WHO). The worldwide researchers and various health professionals are working together to determine the best way to stop its spread or halt this virus's spread and circumvent this pandemic condition threatening millions of human lives. The absence of definitive treatment is possible to explore to reduce virus infection and enhance patient recovery. Along with off-label medicines, plasma therapy, vaccines, the researchers exploit the various plants/herbs and their constituents to effectively treat nCoV infection. The present study aimed to present brief and most informative salient features of the numerous facts regarding the SARS-CoV-2, including the structure, genomic sequence, recent mutation, targeting possibility, and various hurdles in research progress, and off-labeled drugs, convalescent plasma therapy, vaccine and plants/herbs for the treatment of coronavirus disease-2019 (COVID-19). Results showed that off-labeled drugs such as hydroxychloroquine, dexamethasone, tocilizumab, antiviral drug (remdesivir, favipiravir), etc., give positive results and approved for use or approved for restricted use in some countries like India. Future research should focus on these possibilities that may allow the development of an effective treatment for COVID-19.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021035392","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 3

Abstract

The outbreak of novel coronavirus (nCoV) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019 in Wuhan, China, has posed an international public health emergency worldwide and forced people to be confined in their homes. This virus is of high-risk category and is declared a pandemic by the World Health Organization (WHO). The worldwide researchers and various health professionals are working together to determine the best way to stop its spread or halt this virus's spread and circumvent this pandemic condition threatening millions of human lives. The absence of definitive treatment is possible to explore to reduce virus infection and enhance patient recovery. Along with off-label medicines, plasma therapy, vaccines, the researchers exploit the various plants/herbs and their constituents to effectively treat nCoV infection. The present study aimed to present brief and most informative salient features of the numerous facts regarding the SARS-CoV-2, including the structure, genomic sequence, recent mutation, targeting possibility, and various hurdles in research progress, and off-labeled drugs, convalescent plasma therapy, vaccine and plants/herbs for the treatment of coronavirus disease-2019 (COVID-19). Results showed that off-labeled drugs such as hydroxychloroquine, dexamethasone, tocilizumab, antiviral drug (remdesivir, favipiravir), etc., give positive results and approved for use or approved for restricted use in some countries like India. Future research should focus on these possibilities that may allow the development of an effective treatment for COVID-19.

COVID-19感染:靶向治疗的可能性。
2019年12月在中国武汉爆发的新型冠状病毒(nCoV)或严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2)已在全球范围内引发国际突发公共卫生事件,迫使人们被限制在家中。这种病毒属于高风险类别,被世界卫生组织(WHO)宣布为大流行。世界各地的研究人员和各种卫生专业人员正在共同努力,以确定阻止其传播或停止这种病毒传播的最佳途径,并避免这种威胁数百万人生命的大流行状况。在缺乏明确治疗的情况下,可以探索减少病毒感染和提高患者康复的方法。除了标签外药物、血浆疗法、疫苗,研究人员还利用各种植物/草药及其成分有效治疗新型冠状病毒感染。本研究旨在简要介绍有关SARS-CoV-2的众多事实的突出特征,包括结构,基因组序列,最近的突变,靶向可能性,研究进展中的各种障碍,以及用于治疗冠状病毒疾病-2019 (COVID-19)的非标签药物,恢复期血浆治疗,疫苗和植物/草药。结果显示,羟氯喹、地塞米松、托珠单抗、抗病毒药物(remdesivir、favipiravir)等超说明书药物的阳性结果在印度等国家已获批准使用或限制使用。未来的研究应集中在这些可能性上,这些可能性可能有助于开发COVID-19的有效治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.50
自引率
18.50%
发文量
27
审稿时长
>12 weeks
期刊介绍: Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields. Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信